Welcome to follow the official account "Zhushi Free Account"
Recently, with the sharp relaxation of epidemic policies, Yiling Pharmaceutical's short-term employment recruitment news flooded the screen, and the topic of masks containing Lianhua Qingwen has become popular. Yiling Pharmaceutical's gained an astonishing , and it has also won the daily limit many times, and has also become a new favorite in the major stock groups. Yiling Pharmaceutical rose from a low of 18.82 yuan at the end of September 2022 to a high of 53.96 yuan on December 8, up nearly three times in more than two months.
Today I will briefly analyze Yiling Pharmaceutical with you.
1. What does Yiling Pharmaceutical do?
Company was founded in 2001. is mainly based on the research and development, production and sales of traditional Chinese medicine . In recent years, it has also begun to lay out the chemical medicine and big health business segments, forming a health pharmaceutical industry pattern with the coordinated development of traditional Chinese medicine + chemical medicine + big health.
1, Chinese medicine sector
cardiovascular and cerebrovascular drugs (revenue accounts for 40.85% in 2021): Three major products are: Tongxinluo Capsules , Shensong Yangxin Capsules and Qifeng Qiangxin Capsules Mainly;
anti-cold drugs (revenue accounts for 45.87% in 2021): What everyone is well-known is Lianhua Qingwen Capsule ;
and the above two types of drugs are basically the main sources of the company's revenue. Others include
diabetic , yangzhengxiaoji capsules in the tumor field, and nervous system newly launched Jieyu Kufan Capsules, Yishen Yangxin Anshen Tablets, etc.
2. The chemical drug sector is mainly the research and development of innovative drugs and generic drugs.
3. The big health industry sector mainly uses some respiratory health products created by the Lianhua brand.
2. Can Yiling Pharmaceutical currently buy it?
1, from the fundamentals of
(1) Valuation
Price-to-earnings ratio and price-to-book ratio are both in an overvaluable position, especially the price-to-book ratio is seriously overvaluable.
P/E ratio:
P/B/P/B ratio:
(2) Third quarter performance of 2022
The company's revenue in the first three quarters was 7.95 billion yuan (-2%), and its net profit attributable to shareholders was 1.41 billion yuan (+15.58%), and its net profit attributable to shareholders was 1.42 billion yuan (+20.6%) after deducting non-operating items. In the third quarter, the operating income was 2.38 billion yuan (+7.41%); the net profit attributable to shareholders was 366 million yuan (+40.92%), and the net profit attributable to shareholders was 365 million yuan (+49.32%) after deducting non-operating items. was mainly due to a sharp decline in sales expenses, resulting in the growth of profit at side exceeding expectations.
(3) Earnings forecast
2023-2024, according to the brokerage forecast, the annualized growth rate of revenue is about 16%, and the annualized growth rate of net profit attributable to shareholders is about 20% . It is OK, but it is not particularly high. Corresponding to the current price-to-earnings ratio of , this performance growth is a bit low.
The State Council has recently released a reference table for common medicines for COVID-19. It is not only Lianhua Qingwen that applies to the symptoms of fever. Will Lianhua Qingwen Capsules really bring significant performance growth to Yiling Pharmaceutical in the future?
(4) Historical performance
Before the epidemic, the company's non-net profit increased by only 136 million in the five years from 2015 to 2019, which can be said to be very poor in operation. After the outbreak of the epidemic, net profit doubled and increased significantly, which was entirely due to the epidemic.
2. From the technical indicators,
(1) turnover rate
turnover rate reflects the activity of stocks, and it is better to increase it appropriately.However, if the turnover rate exceeds 10% in a row, you should pay attention to it. Yiling Pharmaceutical's short-term turnover rate is too high . From November 16 to December 9, most of them exceeded 10%, and many even exceeded 15%, which also shows that Yiling Pharmaceutical's popularity is very high, and even a bit too high.
At the same time, we can find that has diverged from buying and selling, and the selling trend is stronger than buying. In the past two days, the main funds of have been significantly outflowed, so we need to pay attention to risks.
(2) share price strength RPS
RPS mainly measures the ranking of stocks over the past period of time relative to other stocks. Yiling Pharmaceutical's RPS120 just exceeded 90% on November 14. Currently, RPS120 has exceeded 100%, which means that the increase exceeds all other stocks in the market. This also shows that Yiling Pharmaceutical's stock price has just strengthened in this month , which is very worth paying attention to. If the valuation and fundamentals are good, it is worth buying. However, its valuation is too high, and its performance is mainly driven by Lianhua Qingwen's sales. I personally think it is not a particularly worth buying.
(3) Northbound funds
Northbound funds fell from 3.76% on November 11 to 2.54% on December 9, a decrease of 1.24%, indicating that Northbound funds are not optimistic about Yiling Pharmaceutical in the short term.
(4) weekly line technical pattern
From the weekly line, after about half a year of adjustment, this round has broken through in October, with a short-term increase of nearly 3 times, with a huge increase. , but recently there have been significant changes in a single week, so the short-term upward pressure is relatively high, so you need to be cautious when buying. After pulls back to , it may continue to break through upward.
In addition, Yiling Pharmaceutical recently applied for the patent for the manufacture of medical protective products using Lianhua Qingwen extract. This has not been scientifically proved. At present, there is no evidence to prove that masks are effective. There is also Lianhua Qingwen Capsules that cannot treat new crown , and can only relieve fever symptoms. Yiling Pharmaceutical uses Lianhua Qingwen masks to hype it up, and its eating habits are a bit ugly.
Regarding whether to stock up on medicine:
Recently, Zhong Nanshan Hospital publicly stated that the risk of sequelae of new coronavirus caused by Omickron strain is significantly reduced, and asymptomatic infected people with basically have no sequelae of new coronavirus. Omickron infection is not scary. 99% can fully recover within 7-10 days, and the focus should be on preventing and controlling severe illnesses. It is recommended that there is no need to stock up on medicine too much, just prepare some appropriately, and protect yourself when traveling.
( Statement: The companies involved in this article are for research and analysis only, and the views in this article are only for personal consideration and do not constitute any investment advice)
